鼻腔手术治疗难治性药物性鼻炎的长期结局
这项前瞻性队列研究评估了鼻腔手术治疗难治性药物性鼻炎的长期结局,定义为难治性药物性鼻炎患者每日连续使用鼻减充血剂至少4周且药物治疗无效。共纳入56例患者,中位随访3.4年,91.1%完全停用减充血剂,持续使用者合并哮喘的比值比更高且症状改善更差。结论认为手术重建鼻腔气道与长期停用减充血剂及症状改善相关。
要点
- 难治性药物性鼻炎患者接受鼻腔手术后91.1%完全停用减充血剂。
- 持续使用减充血剂者合并哮喘的OR为16.33,症状改善更差。
- 持续使用者更常继续使用鼻用糖皮质激素(OR 24.0)和盐水喷雾(OR 16.3)。
核心结论
- 手术重建鼻腔气道与药物难治性药物性鼻炎患者的长期停用减充血剂及症状改善相关。
研究设计与样本
- 前瞻性队列研究,纳入56例难治性药物性鼻炎患者,接受鼻腔手术治疗,随访至少12个月。
- 难治性药物性鼻炎定义为尽管接受药物治疗,仍每日连续使用鼻减充血剂至少4周。
- 排除合并鼻窦疾病和非鼻炎状况的患者。
主要发现
- 中位随访3.4年(范围1.6-6.2年),91.1%完全停用减充血剂,5.4%间歇使用,3.6%每日使用。
- 持续使用者症状改善更差:ΔSNOT22为-4.6(SD 15.7) vs 27.1(SD 17),p=0.009;ΔNSS为-1.0(SD 4.2) vs -6.6(SD 5.1),p=0.025。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited treatment options exist for refractory Rhinitis Medicamentosa (RM). The role of surgery after failed medical management is not well defined. Mucosal contact points and restricted airflow often perpetuate decongestant use. This study assessed the long-term outcomes of nasal surgery in patients with refractory RM. METHODS: A prospective cohort study of refractory RM treated with nasal surgery was performed with ≥12 months follow-up. Refractory RM was defined as nasal decongestant use once per day continuously for ≥4 weeks despite medical therapy. Patients with concomitant sinus disease and nonrhinitis conditions were excluded. Sinonasal Outcome Test (SNOT22), Nasal Symptom Score (NSS), and nasal medication use were assessed. Patients who ceased decongestants were compared with ongoing users. RESULTS: A total of 56 patients (age 48.4 [5.0] years, 50% female) were assessed. Median follow-up was 3.4(1.6-6.2) years. Total cessation of decongestants was achieved in 91.1%, while 5.4% had intermittent use, and 3.6% reported daily use. Ongoing users had higher odds of concomitant asthma (40.0% vs. 3.9%; odds ratio [OR], 16.33 [1.7-159.75]; p = 0.036), reduced symptom improvement (ΔSNOT22, -4.6 [15.7] vs. 27.1 [17], p = 0.009 and ΔNSS, -1.0 [4.2] vs. -6.6 [5.1], p = 0.025), and greater ongoing use of nasal corticosteroid (60.0% vs. 5.9%; OR 24.0 [2.8-203.1]) and saline sprays (40% vs. 3.9%; OR 16.3 [1.7-159.8]) but showed no difference in allergy status (OR, 0.7[0.1-7.1]), previous surgery (OR, 1.0[0.1-10.2]), gastroesophageal reflux (OR 1.0[0.1-10.2], or underlying anxiety/depression (OR 6.1[0.8-45.9]) compared with those who ceased. CONCLUSION: Surgically re-establishing a nasal airway was associated with long-term decongestant cessation and symptom improvement in medically refractory RM.
引用
- Li W, Misra S, Harvey RJ, et al. Long-term treatment outcomes in refractory rhinitis medicamentosa managed with nasal surgery. Int Forum Allergy Rhinol. 2023. PMID: 37449456. doi:10.1002/alr.23240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。